Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Abstract PARP inhibitors have revolutionized the management of ovarian cancer and are being licenced for other cancer indications. The clinical trials prompting licencing decisions in ovarian cancer were dominated by white participants or participant ethnicity was not documented. To compensate for this, replicative studies like L-MOCA can be run in specific ethnic groups. In future, strategies such as mandatory collection and publication of race and ethnicity data are essential alongside concerted efforts to widen the inclusivity of trial recruitment.

Original publication

DOI

10.1158/1078-0432.ccr-22-0442

Type

Journal article

Journal

Clinical cancer research

Publisher

American Association for Cancer Research (AACR)

Publication Date

31/03/2022